PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
0.90%
Net income growth under 50% of MCHP's 15.09%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-2.16%
Negative yoy D&A while MCHP is 10.53%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-248.39%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-7.02%
Both cut yoy SBC, with MCHP at -5.57%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
37.95%
Less working capital growth vs. MCHP's 415.09%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
-131.82%
Both yoy AR lines negative, with MCHP at -0.08%. Martin Whitman would suspect an overall sector lean approach or softer demand.
46.84%
Inventory growth well above MCHP's 48.21%. Michael Burry would suspect potential future write-down risk if demand does not materialize.
100.00%
Lower AP growth vs. MCHP's 214.27%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
42.93%
Lower 'other working capital' growth vs. MCHP's 137.71%. David Dodd would see fewer unexpected short-term demands on cash.
No Data
No Data available this quarter, please select a different quarter.
22.29%
Operating cash flow growth 1.25-1.5x MCHP's 18.61%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
-42.27%
Negative yoy CapEx while MCHP is 6.65%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
6.30%
Some yoy expansion while MCHP is negative at -128.05%. John Neff sees competitor possibly refraining from new investments or liquidating existing ones for immediate cash.
-51.33%
We reduce yoy sales while MCHP is 12.88%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
No Data
No Data available this quarter, please select a different quarter.
-963.49%
Both yoy lines negative, with MCHP at -355.88%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-48.57%
Negative yoy issuance while MCHP is 104.64%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
41.37%
Buyback growth of 41.37% while MCHP is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.